TScan Therapeutics (NASDAQ:TCRX) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report published on Monday morning, Marketbeat.com reports. Wedbush currently has a $10.00 target price on the stock.

TCRX has been the subject of a number of other research reports. BTIG Research began coverage on TScan Therapeutics in a research report on Thursday, May 16th. They issued a buy rating and a $12.00 target price for the company. HC Wainwright reaffirmed a buy rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 4th. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics currently has an average rating of Buy and a consensus price target of $12.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $5.63 on Monday. The business has a 50 day moving average of $6.81 and a 200 day moving average of $7.16. The company has a market capitalization of $297.62 million, a price-to-earnings ratio of -4.40 and a beta of 0.83. TScan Therapeutics has a 1-year low of $1.97 and a 1-year high of $9.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.23 and a quick ratio of 5.23.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%. On average, sell-side analysts predict that TScan Therapeutics will post -1.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

A number of large investors have recently bought and sold shares of TCRX. abrdn plc purchased a new position in shares of TScan Therapeutics during the fourth quarter valued at approximately $1,166,000. Tocqueville Asset Management L.P. purchased a new position in shares of TScan Therapeutics during the first quarter valued at approximately $1,685,000. Pale Fire Capital SE increased its stake in shares of TScan Therapeutics by 30.2% during the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after buying an additional 4,998 shares during the period. Vanguard Group Inc. increased its stake in shares of TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the period. Finally, Cannon Global Investment Management LLC purchased a new position in shares of TScan Therapeutics during the first quarter valued at approximately $139,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.